Clinical Trial Update: Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention [Phase 4]

View source ↗

Summary

Phase 4 trial comparing Inclisiran to placebo to prevent major adverse cardiovascular and limb events in patients undergoing PCI or peripheral endovascular inte…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Peripheral Artery Disease

Drugs mentioned

• Inclisiran (inclisiran)

Snippet

Sponsor: Duke University | Conditions: Percutaneous Coronary Intervention, Peripheral Endovascular Intervention | Phase 4 | Status: RECRUITING